Contract manufacturing of bulk COVID-19 vaccine drug substance for AstraZeneca
First written in FY2021-Q3. 4 of 8 entries say "Advanced", first in FY2021. Latest entry: FY2024-Q2.
No other company in this theme has enough history to compare yet.
- FY2024-Q2RestatedAnnual report
「Although the end as scheduled of contracted domestic manufacture of the drug substance of AstraZeneca K.K.'s vaccine against the novel coronavirus reduced revenue, strong performance by core products and an increase in contract fee income resulted in a year-on-year increase in net sales.」
The Company reconfirmed that contracted domestic manufacture of AstraZeneca K.K.'s vaccine drug substance had ended as scheduled. - FY2023-Q2RestatedAnnual report
「Total net sales decreased year on year, primarily because the contracted domestic manufacture of the drug substance of AstraZeneca K.K.'s vaccine against the novel coronavirus ended as scheduled.」
The Company reconfirmed that contracted domestic manufacture of AZD1222 drug substance had ended as scheduled. First-half net sales from AZD1222 drug substance amounted to ¥1,931 million. - FY2022AchievedAnnual report
「In manufacturing the drug substance of AstraZeneca's vaccine against the novel coronavirus, the Company advanced its efforts to fulfill its social responsibility as a company with biopharmaceutical manufacturing technology and contribute to bringing the pandemic under control, completing manufacture of the drug substance in the planned quantity.」
For the contract manufacture of AZD1222 drug substance, the Company completed manufacture of the planned quantity of drug substance and concluded manufacturing activities for the business. Net sales for FY2022 amounted to ¥14,375 million. - FY2022-Q3AdvancedAnnual report
「In addition to the commencement of sales of the drug substance of AstraZeneca K.K.'s vaccine against the novel coronavirus in March 2021, contract fee income increased year on year, resulting in a substantial year-on-year increase in total net sales.」
Sales of AZD1222 drug substance continued, and cumulative net sales for the first 3 quarters amounted to ¥12,553 million. This was an increase from ¥8,046 million in the cumulative period through the previous quarter and contributed substantially to the increase in net sales. - FY2022-Q2AdvancedAnnual report
「In addition to the commencement of sales of the drug substance of AstraZeneca K.K.'s vaccine against the novel coronavirus in March 2021, contract fee income increased year on year, resulting in a substantial year-on-year increase in total net sales.」
Revenue from AstraZeneca K.K.'s AZD1222 drug substance amounted to ¥8,046 million in the first half, representing a substantial progression in its contribution to revenue from the sales-launch stage in the previous quarter. - FY2022-Q1AdvancedAnnual report
「In addition, sales of the drug substance of AstraZeneca K.K.'s vaccine against the novel coronavirus began in March 2021, and sales of Izcargo® I.V. Infusion 10 mg, which was listed for reimbursement in May 2021, also began. As a result, total net sales increased year on year.」
The contract manufacture of COVID-19 vaccine drug substance for AstraZeneca progressed to sales commencement in March 2021 and the recognition of ¥3,671 million in revenue. This was a substantial increase from the ¥404 million in contract manufacturing revenue recorded in the previous fiscal year. - FY2021AdvancedAnnual report
「In addition, from December 2020, the Company has been contracted by AstraZeneca K.K. to manufacture the drug substance of its novel coronavirus vaccine, AZD1222, in Japan. Net sales for the consolidated fiscal year amounted to ¥404 million.」
The contract manufacture of COVID-19 vaccine drug substance for AstraZeneca progressed from the contract-signing stage to the manufacturing and revenue-recognition stage, resulting in ¥404 million in net sales for the fiscal year ended March 2021. - FY2021-Q3First statedAnnual report
「In December 2020, the Company entered into a contract manufacturing agreement with AstraZeneca K.K. for the domestic manufacture of the drug substance of AZD1222, a COVID-19 vaccine based on an adenovirus vector being developed by AstraZeneca K.K.」
In December 2020, the Company entered into a contract manufacturing agreement for the domestic manufacture of the drug substance of AZD1222, a COVID-19 vaccine being developed by AstraZeneca K.K. The Company stated that it would promptly disclose the impact on current-period results if disclosure became necessary.